CNTO 148
Phase 3Small molecule
Johnson & JohnsonCNTO 148 is one of 265 small molecule programs targeting Palmoplantar Pustulosis. It is currently in Phase 3.
10
Indications
19
Total Trials
0
Active Trials
264
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1CNTO 148
Johnson & JohnsonPhase 3
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Cinqair
TevaPreclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Rheumatoid Arthritis5 trials
Psoriasis3 trials
Age-Related Macular Degeneration1 trial
Lupus Nephritis1 trial
8 more indications
Immunogenicity1 trial
Geographic Atrophy1 trial
Chronic Obstructive Pulmonary Disease1 trial
Type 2 Diabetes Mellitus1 trial
Asthma1 trial
Palmoplantar Pustulosis1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CNTO 148. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company